Regeneron amends $720M lease financing to align covenants with Dec 2022 credit agreement

REGENERON PHARMACEUTICALS, INC.

Third A&R Participation Agreement aligns financial and operating covenants with credit agreement entered December 2022.
$720 million lease financing for corporate headquarters; maturity remains March 2027 with 5-year extension option.
Yield on advances unchanged, based on 1-month SOFR term rate plus spread and margin tied to debt rating/leverage.
No new borrowing; amendment and restatement of existing facility; lease term extended previously to 2027.
Regeneron guarantees obligations; subsidiary guarantors only join if they have borrowings under the credit agreement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.